Advanced (3D/4D) Visualizations Systems Market Driven by Numerous Cancer Cases

A recently added report by TMR Research, titled, “Advanced (3D/4D) Visualization Systems Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017–2025,” offers important information on the size of the market, the prevalent competitive dynamics in it, a qualitative analysis of growth drivers and restraints shaping its contours, and its prospects going forward.
The market for advanced (3D/4D) visualization systems, which aid in diagnosing and treating different cardiology, oncology, and neurology cases, is seeing swift growth due to the increasing instances of cancer globally and also due to the rise in different cardiovascular diseases that often result in death. Besides, the legal requirements set by the U.S. Food and Drug Administration (FDA) pertaining to the maintenance of picture archiving and communications system (PACS) records has generated a need to digitize patient data. This is slated to have a positive impact on the uptake of advanced (3D/4D) visualization systems too.
Further, advanced (3D/4D) visualization systems serve to bring down costs through effective diagnosis. This will likely generate greater opportunities in the market in the upcoming years.
One factor posing a roadblock to the global market for advanced (3D/4D) visualization systems is the steep cost of equipment. However, the increasing instances of chronic diseases along with the development of novel software and services will help to overcome the deterrent. Besides, continued improvement in healthcare infrastructure, progress in computer technology, and demand for improved imaging technology are also pushing up demand in the market.
From a geographical standpoint, North America at present accounts for maximum demand in the advanced (3D/4D) visualization systems market due to a solid healthcare infrastructure, awareness among the patients, and quick uptake of cutting-edge technology. The market in Europe is also predicted to demonstrate good growth on the back of rising healthcare expenditure. Further, Asia Pacific, powered by emerging economies of China, India, and Malaysia, will see good growth on account of a massive under-served patient population and the thrust on research and development programs pertaining to healthcare infrastructure. However, high upfront costs involved in installing the systems are posing a hindrance to the market in the region.
In order to comprehend the competition prevailing in the global market for advanced (3D/4D) visualization systems, the report profiles prominent companies such as Carestream Health, Inc., QI Imaging, LLC, Fujifilm Holding America Corporation, CONMED Corporation, Toshiba Medical Systems Corporation, GE Healthcare, Philips Healthcare, Intelerad Medical Systems Inc., Siemens Healthcare, Terarecon, Inc., Visage Imaging, and Visualization Sciences Group. It studies their revenues, market shares, key strategies, and possible future trajectory in details.

Source:https://tmrresearchblog.com/advanced-3d4d-visualizations-market-driven-numerous-cancer-cases/

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more